MAP2K7 and hepatocellular carcinoma: The multi-tyrosine kinase inhibitor sorafenib (FDA-approved) is used in HCC patients to inhibit angiogenesis-inducing cytokine VEGF and the MAP Kinase, Raf/Mek/Erk pathways.